Literature DB >> 28868352

SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer.

Amrita M Nargund1, Hatice U Osmanbeyoglu2, Emily H Cheng1,3, James J Hsieh4.   

Abstract

Mutations within chromatin modulating protein complexes have dominated the novel cancer gene landscape. However, little is known about how individual aberrations contribute to cancer formation. A novel Pbrm1 kidney cancer mouse model examining the role of Pbrm1 provides much needed clue concerning how SWI/SNF complexes might function as tumor suppressors.

Entities:  

Keywords:  BAF180; Clear Cell Kidney Cancer Mouse Model; Genomic Biomarkers; MTOR; PBRM1; SWI/SNF Chromatin Remodeling Tumor Suppressor Gene; VHL

Year:  2017        PMID： 28868352      PMCID： PMC5540208          DOI： 10.1080/23723556.2017.1342747

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.

Authors:  Wenhua Gao; Wei Li; Tengfei Xiao; Xiaole Shirley Liu; William G Kaelin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-12       Impact factor: 11.205

Review 2.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.

Authors:  Gregg L Semenza
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

3.  Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.

Authors:  Jianing Xu; Can G Pham; Steven K Albanese; Yiyu Dong; Toshinao Oyama; Chung-Han Lee; Vanessa Rodrik-Outmezguine; Zhan Yao; Song Han; David Chen; Daniel L Parton; John D Chodera; Neal Rosen; Emily H Cheng; James J Hsieh
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

Review 4.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

5.  The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.

Authors:  Amrita M Nargund; Can G Pham; Yiyu Dong; Patricia I Wang; Hatice U Osmangeyoglu; Yuchen Xie; Omer Aras; Song Han; Toshinao Oyama; Shugaku Takeda; Chelsea E Ray; Zhenghong Dong; Mathieu Berge; A Ari Hakimi; Sebastien Monette; Carl L Lekaye; Jason A Koutcher; Christina S Leslie; Chad J Creighton; Nils Weinhold; William Lee; Satish K Tickoo; Zhong Wang; Emily H Cheng; James J Hsieh
Journal:  Cell Rep       Date:  2017-03-21       Impact factor: 9.423

6.  Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

Authors:  James J Hsieh; David Chen; Patricia I Wang; Mahtab Marker; Almedina Redzematovic; Ying-Bei Chen; S Duygu Selcuklu; Nils Weinhold; Nancy Bouvier; Kety H Huberman; Umesh Bhanot; Michael S Chevinsky; Parul Patel; Patrizia Pinciroli; Helen H Won; Daoqi You; Agnes Viale; William Lee; A Ari Hakimi; Michael F Berger; Nicholas D Socci; Emily H Cheng; Jennifer Knox; Martin H Voss; Maurizio Voi; Robert J Motzer
Journal:  Eur Urol       Date:  2016-10-15       Impact factor: 20.096

Review 7.  Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.

Authors:  James J Hsieh; Brandon J Manley; Nabeela Khan; JianJiong Gao; Maria I Carlo; Emily H Cheng
Journal:  Semin Cell Dev Biol       Date:  2016-09-08       Impact factor: 7.727

8.  A clear picture of renal cell carcinoma.

Authors:  A Ari Hakimi; Can G Pham; James J Hsieh
Journal:  Nat Genet       Date:  2013-08       Impact factor: 38.330

9.  Comprehensive molecular characterization of clear cell renal cell carcinoma.

Authors: 
Journal:  Nature       Date:  2013-06-23       Impact factor: 49.962

10.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

Authors:  Ignacio Varela; Patrick Tarpey; Keiran Raine; Dachuan Huang; Choon Kiat Ong; Philip Stephens; Helen Davies; David Jones; Meng-Lay Lin; Jon Teague; Graham Bignell; Adam Butler; Juok Cho; Gillian L Dalgliesh; Danushka Galappaththige; Chris Greenman; Claire Hardy; Mingming Jia; Calli Latimer; King Wai Lau; John Marshall; Stuart McLaren; Andrew Menzies; Laura Mudie; Lucy Stebbings; David A Largaespada; L F A Wessels; Stephane Richard; Richard J Kahnoski; John Anema; David A Tuveson; Pedro A Perez-Mancera; Ville Mustonen; Andrej Fischer; David J Adams; Alistair Rust; Waraporn Chan-on; Chutima Subimerb; Karl Dykema; Kyle Furge; Peter J Campbell; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2011-01-19       Impact factor: 49.962
  10 in total
  4 in total

Review 1.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

2.  Identification of methylation-driven genes related to prognosis in clear-cell renal cell carcinoma.

Authors:  Jia Wang; Qiujing Zhang; Qingqing Zhu; Chengxiang Liu; Xueli Nan; Fuxia Wang; Lihua Fang; Jie Liu; Chao Xie; Shuai Fu; Bao Song
Journal:  J Cell Physiol       Date:  2019-07-05       Impact factor: 6.384

3.  PBRM1 deficiency oncogenic addiction is associated with activated AKT-mTOR signalling and aerobic glycolysis in clear cell renal cell carcinoma cells.

Authors:  Yu Tang; Yan-Hong Jin; Hu-Li Li; Hui Xin; Jin-Dong Chen; Xue-Ying Li; You-Fu Pan
Journal:  J Cell Mol Med       Date:  2022-06-07       Impact factor: 5.295

Review 4.  Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma.

Authors:  James J Hsieh; Valerie H Le; Toshinao Oyama; Christopher J Ricketts; Thai Huu Ho; Emily H Cheng
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.